Exact Mass: 814.4660782

Goyaglycoside h

C42H70O15 (814.471447)

Goyaglycoside h is found in fruits. Goyaglycoside h is a constituent of Momordica charantia (bitter melon). Constituent of Momordica charantia (bitter melon). Goyaglycoside h is found in fruits.

PA(20:2(11Z,14Z)/6 keto-PGF1alpha)

C43H75O12P (814.499588)

PA(20:2(11Z,14Z)/6 keto-PGF1alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:2(11Z,14Z)/6 keto-PGF1alpha), in particular, consists of one chain of one 11Z,14Z-eicosadienoyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(6 keto-PGF1alpha/20:2(11Z,14Z))

C43H75O12P (814.499588)

PA(6 keto-PGF1alpha/20:2(11Z,14Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(6 keto-PGF1alpha/20:2(11Z,14Z)), in particular, consists of one chain of one 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of 11Z,14Z-eicosadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:2(11Z,14Z)/TXB2)

C43H75O12P (814.499588)

PA(20:2(11Z,14Z)/TXB2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:2(11Z,14Z)/TXB2), in particular, consists of one chain of one 11Z,14Z-eicosadienoyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(TXB2/20:2(11Z,14Z))

C43H75O12P (814.499588)

PA(TXB2/20:2(11Z,14Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(TXB2/20:2(11Z,14Z)), in particular, consists of one chain of one Thromboxane B2 at the C-1 position and one chain of 11Z,14Z-eicosadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C45H67O11P (814.4420762)

PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

C45H67O11P (814.4420762)

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PG(16:1(9Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C42H71O13P (814.4632045999999)

PG(16:1(9Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(16:1(9Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one 9Z-hexadecenoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

PG(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/16:1(9Z))

C42H71O13P (814.4632045999999)

PG(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/16:1(9Z)) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/16:1(9Z)), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of 9Z-hexadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

PG(18:3(6Z,9Z,12Z)/5-iso PGF2VI)

C42H71O13P (814.4632045999999)

PG(18:3(6Z,9Z,12Z)/5-iso PGF2VI) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(18:3(6Z,9Z,12Z)/5-iso PGF2VI), in particular, consists of one chain of one 6Z,9Z,12Z-octadecatrienoyl at the C-1 position and one chain of 5-iso Prostaglandin F2alpha-VI at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

PG(5-iso PGF2VI/18:3(6Z,9Z,12Z))

C42H71O13P (814.4632045999999)

PG(5-iso PGF2VI/18:3(6Z,9Z,12Z)) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(5-iso PGF2VI/18:3(6Z,9Z,12Z)), in particular, consists of one chain of one 5-iso Prostaglandin F2alpha-VI at the C-1 position and one chain of 6Z,9Z,12Z-octadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

PG(18:3(9Z,12Z,15Z)/5-iso PGF2VI)

C42H71O13P (814.4632045999999)

PG(18:3(9Z,12Z,15Z)/5-iso PGF2VI) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(18:3(9Z,12Z,15Z)/5-iso PGF2VI), in particular, consists of one chain of one 9Z,12Z,15Z-octadecatrienoyl at the C-1 position and one chain of 5-iso Prostaglandin F2alpha-VI at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

PG(5-iso PGF2VI/18:3(9Z,12Z,15Z))

C42H71O13P (814.4632045999999)

PG(5-iso PGF2VI/18:3(9Z,12Z,15Z)) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(5-iso PGF2VI/18:3(9Z,12Z,15Z)), in particular, consists of one chain of one 5-iso Prostaglandin F2alpha-VI at the C-1 position and one chain of 9Z,12Z,15Z-octadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

PG(a-17:0/PGJ2)

C43H75O12P (814.499588)

PG(a-17:0/PGJ2) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(a-17:0/PGJ2), in particular, consists of one chain of one 14-methylhexadecanoyl at the C-1 position and one chain of Prostaglandin J2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

PG(PGJ2/a-17:0)

C43H75O12P (814.499588)

PG(PGJ2/a-17:0) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(PGJ2/a-17:0), in particular, consists of one chain of one Prostaglandin J2 at the C-1 position and one chain of 14-methylhexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

PG(i-17:0/PGJ2)

C43H75O12P (814.499588)

PG(i-17:0/PGJ2) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(i-17:0/PGJ2), in particular, consists of one chain of one 15-methylhexadecanoyl at the C-1 position and one chain of Prostaglandin J2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

PG(PGJ2/i-17:0)

C43H75O12P (814.499588)

PG(PGJ2/i-17:0) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(PGJ2/i-17:0), in particular, consists of one chain of one Prostaglandin J2 at the C-1 position and one chain of 15-methylhexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

PGP(i-14:0/18:1(12Z)-O(9S,10R))

C38H72O14P2 (814.4397072)

PGP(i-14:0/18:1(12Z)-O(9S,10R)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-14:0/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

PGP(18:1(12Z)-O(9S,10R)/i-14:0)

C38H72O14P2 (814.4397072)

PGP(18:1(12Z)-O(9S,10R)/i-14:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(18:1(12Z)-O(9S,10R)/i-14:0), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

PGP(i-14:0/18:1(9Z)-O(12,13))

C38H72O14P2 (814.4397072)

PGP(i-14:0/18:1(9Z)-O(12,13)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-14:0/18:1(9Z)-O(12,13)), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

PGP(18:1(9Z)-O(12,13)/i-14:0)

C38H72O14P2 (814.4397072)

PGP(18:1(9Z)-O(12,13)/i-14:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(18:1(9Z)-O(12,13)/i-14:0), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

Aesculioside Ie

C41H66O16 (814.4350636)

Beesioside H

C42H70O15 (814.471447)

Vina-ginsenoside R25

C42H70O15 (814.471447)

Tarecilioside F

C42H70O15 (814.471447)

Tarecilioside G

C42H70O15 (814.471447)

Lonomycin C

C43H74O14 (814.5078304)

(20R,24S)-6-O-beta-D-glucopyranosyl-25-O-beta-D-glucopyranosyl-3beta,6alpha,16beta,25-tetrahydroxy-20,24-epoxycycloartane|astramembranoside A|cycloastragenol 6,25-di-O-beta-D-glucopyranoside

C42H70O15 (814.471447)

C43H74O14

C43H74O14 (814.5078304)

C42H70O15

C42H70O15 (814.471447)

vernocuminoside G

C41H66O16 (814.4350636)

thalicoside G1

C42H70O15 (814.471447)

3beta,16alpha, 21, 24, 28-pentahydroxystigmastane-7(8),9(11)-dien-3,28-dioxy-beta-D-glucopyranoside|vernonioside S3

C41H66O16 (814.4350636)

Dregoside Da1

C42H70O15 (814.471447)

(3beta,5alpha,22alpha,25R)-Furostane-3,17,22,26-tetrol

C42H70O15 (814.471447)

olean-12-ene-3beta,6beta,16beta,21beta,23-pentaol 3-O-beta-glucopyranosyl-16-O-beta-glucopyranoside

C42H70O15 (814.471447)

(20R)-16-O-[6-O-methyl-beta-D-galactofuranosyl-(1->3)-(6-O-methyl-beta-D-galactofuranosyl)]-24-methyl-5alpha-cholest-8(14),24(28)-diene-3beta,4beta,6beta,7beta,16alpha-pentol|anthenoside C

C42H70O15 (814.471447)

25-methoxy-3beta,7beta,20(S),22-tetrahydroxydammar-23-ene-3-O-alpha-L-rhamnopyranosyl-(1->2)-beta-D-glucopyranoside|sapinmusaponin D

C43H74O14 (814.5078304)

arjungenin-23,28-bis-O-glucopyranoside I

C41H66O16 (814.4350636)

3,3-bis[(E)-3,7-dimethylocta-2,6-dienyl]-7-hydroxy-9-methoxy-3,3,5,5-tetramethyl-3,3,11,11-tetrahydro-8,10-bipyrano[3,2-a]carbazol|bisgerayafoline B

C55H62N2O4 (814.4709332)

3-O-beta-d-glucopyranosyl-29-O-beta-d-glucopyranosyl-3beta,6beta,16beta,23,29-pentahydroxyolean-12-ene

C42H70O15 (814.471447)

22S,25-epoxy-3-O-beta-D-galactopyranosyl-29-O-beta-D-glucopyranosyl-9beta,19-cyclo-20S-lanostane-3beta,16beta,24S,29-tetrol

C42H70O15 (814.471447)

3,3-bis[(E)-3,7-dimethylocta-2,6-dienyl]-8-hydroxy-9-methoxy-3,3,5,5-tetramethyl-3,3,11,11-tetrahydro-7,10-bipyrano[3,2-a]carbazol|bisgerayafoline A

C55H62N2O4 (814.4709332)

21-O-(beta-D-glucopyranosyl-(1->2)-beta-D-glucopyranosyl)-3beta,16beta,21beta,23,28-pentahydroxyolean-12-en|pleurosaponin C

C42H70O15 (814.471447)

trachelosperoside B-2

C41H66O16 (814.4350636)

20R,24S-epoxycycloartan-3beta,6alpha,16beta,25-tetraol 3-O-[beta-D-glucopyranosyl(1->2)]-beta-D-glucopyranoside|cyclosiversigenin 3-O-[beta-D-glucopyranosyl(1->2)]-beta-D-glucopyranoside|cyclounifolioside B

C42H70O15 (814.471447)

C41H66O16

C41H66O16 (814.4350636)

teikaside BL-Ic

C42H70O15 (814.471447)

cycloaraloside E

C42H70O15 (814.471447)

thalicoside G2

C42H70O15 (814.471447)

ASTRAVERSIANIN XIV

C42H70O15 (814.471447)

PG(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

C46H71O10P (814.4784596)

PG(20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))

C46H71O10P (814.4784596)

PG(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z))

C46H71O10P (814.4784596)

PI(13:0/20:5(5Z,8Z,11Z,14Z,17Z))

C42H71O13P (814.4632045999999)

PI(15:1(9Z)/18:4(6Z,9Z,12Z,15Z))

C42H71O13P (814.4632045999999)

PI(18:4(6Z,9Z,12Z,15Z)/15:1(9Z))

C42H71O13P (814.4632045999999)

PI(20:5(5Z,8Z,11Z,14Z,17Z)/13:0)

C42H71O13P (814.4632045999999)

PI(P-16:0/18:4(6Z,9Z,12Z,15Z))

C43H75O12P (814.499588)

Goyaglycoside h

C42H70O15 (814.471447)

PG 40:10

C46H71O10P (814.4784596)

PI 33:5

C42H71O13P (814.4632045999999)

PI O-34:5

C43H75O12P (814.499588)

Dregeoside Da1

C42H70O15 (814.471447)

[4-Butyl-2,3,5,6-tetrafluoro-3-methoxy-2,4,6-tris(1-methylethyl)[1,1:3,1-terphenyl]-2-yl]bis(tricyclo[3.3.1.1(3,7)]dec-1-yl)phosphine

C52H67F4OP (814.486539)

[3-hydroxy-5-(4-hydroxy-4,6-dimethyl-5-propanoyloxyoxan-2-yl)oxy-2-[[(11E,13Z)-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-4-propanoyloxy-1-oxacyclohexadeca-11,13-dien-6-yl]oxy]-6-methyloxan-4-yl]-dimethylazanium

C41H68NO15+ (814.4588718)

PG(a-17:0/PGJ2)

C43H75O12P (814.499588)

PG(PGJ2/a-17:0)

C43H75O12P (814.499588)

PG(i-17:0/PGJ2)

C43H75O12P (814.499588)

PG(PGJ2/i-17:0)

C43H75O12P (814.499588)

PA(20:2(11Z,14Z)/TXB2)

C43H75O12P (814.499588)

PA(TXB2/20:2(11Z,14Z))

C43H75O12P (814.499588)

PA(20:2(11Z,14Z)/6 keto-PGF1alpha)

C43H75O12P (814.499588)

PA(6 keto-PGF1alpha/20:2(11Z,14Z))

C43H75O12P (814.499588)

PG(18:3(6Z,9Z,12Z)/5-iso PGF2VI)

C42H71O13P (814.4632045999999)

PG(5-iso PGF2VI/18:3(6Z,9Z,12Z))

C42H71O13P (814.4632045999999)

PG(18:3(9Z,12Z,15Z)/5-iso PGF2VI)

C42H71O13P (814.4632045999999)

PG(5-iso PGF2VI/18:3(9Z,12Z,15Z))

C42H71O13P (814.4632045999999)

PGP(i-14:0/18:1(12Z)-O(9S,10R))

C38H72O14P2 (814.4397072)

PGP(18:1(12Z)-O(9S,10R)/i-14:0)

C38H72O14P2 (814.4397072)

PGP(i-14:0/18:1(9Z)-O(12,13))

C38H72O14P2 (814.4397072)

PGP(18:1(9Z)-O(12,13)/i-14:0)

C38H72O14P2 (814.4397072)

PG(16:1(9Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C42H71O13P (814.4632045999999)

PG(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/16:1(9Z))

C42H71O13P (814.4632045999999)

PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C45H67O11P (814.4420762)

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

C45H67O11P (814.4420762)

Operculinoside A

C43H74O14 (814.5078304)

A natural product found in Operculina turpethum.

Goyaglycoside-h

C42H70O15 (814.471447)

Smgdg O-8:0_26:5

C43H74O12S (814.4900724)

Smgdg O-26:5_8:0

C43H74O12S (814.4900724)

Smgdg O-28:5_6:0

C43H74O12S (814.4900724)

Dgdg O-24:4_4:0

C43H74O14 (814.5078304)

Dgdg O-20:4_8:0

C43H74O14 (814.5078304)

Dgdg O-22:4_6:0

C43H74O14 (814.5078304)

Dgdg O-26:4_2:0

C43H74O14 (814.5078304)

Dgdg O-8:0_20:4

C43H74O14 (814.5078304)

Smgdg O-14:1_20:4

C43H74O12S (814.4900724)

Smgdg O-16:2_18:3

C43H74O12S (814.4900724)

Smgdg O-24:5_10:0

C43H74O12S (814.4900724)

Smgdg O-16:0_18:5

C43H74O12S (814.4900724)

Smgdg O-18:3_16:2

C43H74O12S (814.4900724)

Smgdg O-20:4_14:1

C43H74O12S (814.4900724)

Smgdg O-16:1_18:4

C43H74O12S (814.4900724)

Smgdg O-12:0_22:5

C43H74O12S (814.4900724)

Smgdg O-18:2_16:3

C43H74O12S (814.4900724)

Smgdg O-18:1_16:4

C43H74O12S (814.4900724)

Smgdg O-18:4_16:1

C43H74O12S (814.4900724)

Smgdg O-14:0_20:5

C43H74O12S (814.4900724)

Smgdg O-22:5_12:0

C43H74O12S (814.4900724)

Smgdg O-10:0_24:5

C43H74O12S (814.4900724)

Smgdg O-16:4_18:1

C43H74O12S (814.4900724)

Smgdg O-18:5_16:0

C43H74O12S (814.4900724)

Smgdg O-20:5_14:0

C43H74O12S (814.4900724)

Smgdg O-16:3_18:2

C43H74O12S (814.4900724)

Dgdg O-12:0_16:4

C43H74O14 (814.5078304)

Dgdg O-10:0_18:4

C43H74O14 (814.5078304)

Dgdg O-18:4_10:0

C43H74O14 (814.5078304)

Dgdg O-16:4_12:0

C43H74O14 (814.5078304)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoxy]propan-2-yl] decanoate

C43H75O12P (814.499588)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] (Z)-hexadec-9-enoate

C43H75O12P (814.499588)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propan-2-yl] (Z)-tetradec-9-enoate

C43H75O12P (814.499588)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-tetradecoxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C43H75O12P (814.499588)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

C43H75O12P (814.499588)

[1-[(9Z,12Z)-hexadeca-9,12-dienoxy]-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C43H75O12P (814.499588)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C43H75O12P (814.499588)

[1-hexadecoxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C43H75O12P (814.499588)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C43H75O12P (814.499588)

[1-[(Z)-hexadec-9-enoxy]-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C43H75O12P (814.499588)

[1-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-octadec-9-enoate

C43H75O12P (814.499588)

[1-decoxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoate

C43H75O12P (814.499588)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propan-2-yl] hexadecanoate

C43H75O12P (814.499588)

[1-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

C43H75O12P (814.499588)

[1-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoxy]-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] dodecanoate

C43H75O12P (814.499588)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(Z)-octadec-9-enoxy]propan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C43H75O12P (814.499588)

[1-dodecoxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

C43H75O12P (814.499588)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]propan-2-yl] tetradecanoate

C43H75O12P (814.499588)

[1-pentanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C42H70O15 (814.471447)

[1-propanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

C42H70O15 (814.471447)

[1-heptanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C42H70O15 (814.471447)

[1-nonanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C42H70O15 (814.471447)

[3,4,5-trihydroxy-6-[2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxy-3-tetradecanoyloxypropoxy]oxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[6-[3-hexadecanoyloxy-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[3,4,5-trihydroxy-6-[2-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]oxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[6-[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-octadecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[1-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C42H70O15 (814.471447)

[6-[2-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]oxy-3-dodecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[6-[2,3-bis[[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy]propoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[6-[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-[(Z)-octadec-9-enoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[6-[3-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[6-[3-[(Z)-hexadec-9-enoyl]oxy-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

C46H71O10P (814.4784596)

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C46H71O10P (814.4784596)

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

C46H71O10P (814.4784596)

[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (Z)-heptadec-9-enoate

C42H71O13P (814.4632045999999)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

C46H71O10P (814.4784596)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(Z)-pentadec-9-enoyl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C42H71O13P (814.4632045999999)

[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (9Z,12Z)-heptadeca-9,12-dienoate

C42H71O13P (814.4632045999999)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

C46H71O10P (814.4784596)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentadecanoyloxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C42H71O13P (814.4632045999999)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C42H71O13P (814.4632045999999)

[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxypropyl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C46H71O10P (814.4784596)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C42H71O13P (814.4632045999999)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

C42H71O13P (814.4632045999999)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxypropyl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

C46H71O10P (814.4784596)

[(2S,3S,6S)-6-[(2S)-2-[(E)-hexadec-7-enoyl]oxy-3-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2S,3S,6S)-6-[(2S)-3-hexadecanoyloxy-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[1-[(2R,5R,6R)-3,4,5-trihydroxy-6-[[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C42H70O15 (814.471447)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxypropan-2-yl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

C46H71O10P (814.4784596)

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[hydroxy-[(5S)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] (E)-heptadec-7-enoate

C42H71O13P (814.4632045999999)

[(2S,3S,6S)-6-[(2S)-3-[(E)-hexadec-9-enoyl]oxy-2-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2S,3S,6S)-6-[(2S)-2-hexadecanoyloxy-3-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2S,3S,6S)-3,4,5-trihydroxy-6-[(2S)-3-[(5E,8E,11E)-icosa-5,8,11-trienoyl]oxy-2-[(E)-tetradec-9-enoyl]oxypropoxy]oxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2S,3S,6S)-6-[(2S)-3-[(E)-hexadec-7-enoyl]oxy-2-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2S,3S,6S)-3,4,5-trihydroxy-6-[(2S)-3-[(7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoyl]oxy-2-tetradecanoyloxypropoxy]oxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2S,3S,6S)-3,4,5-trihydroxy-6-[(2S)-2-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxy-3-tetradecanoyloxypropoxy]oxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2S,3S,6S)-3,4,5-trihydroxy-6-[(2S)-2-[(8E,11E,14E)-icosa-8,11,14-trienoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropoxy]oxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2R)-1-[hydroxy-[(5S)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-3-[(E)-pentadec-9-enoyl]oxypropan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C42H71O13P (814.4632045999999)

[1-[(2R,5R,6R)-3,4,5-trihydroxy-6-[[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-3-[(E)-undec-4-enoyl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C42H70O15 (814.471447)

[(2S,3S,6S)-3,4,5-trihydroxy-6-[(2S)-2-[(7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoyl]oxy-3-tetradecanoyloxypropoxy]oxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2S,3S,6S)-6-[(2S)-3-hexadecanoyloxy-2-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2S,3S,6S)-6-[(2S)-3-[(E)-hexadec-7-enoyl]oxy-2-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2S)-3-[hydroxy-[(5S)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-2-undecanoyloxypropyl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

C42H71O13P (814.4632045999999)

[(2S,3S,6S)-6-[(2S)-3-[(7E,10E,13E,16E)-docosa-7,10,13,16-tetraenoyl]oxy-2-dodecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2S,3S,6S)-3,4,5-trihydroxy-6-[(2S)-3-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxy-2-tetradecanoyloxypropoxy]oxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2R)-1-[hydroxy-[(5S)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

C42H71O13P (814.4632045999999)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropan-2-yl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

C46H71O10P (814.4784596)

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[hydroxy-[(5S)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] heptadecanoate

C42H71O13P (814.4632045999999)

[(2S,3S,6S)-6-[(2S)-3-decanoyloxy-2-[(5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2S,3S,6S)-6-[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-[(10E,12E)-octadeca-10,12-dienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2R,3R,6R)-6-[(2S)-2-decanoyloxy-3-[(5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxypropyl] (6E,9E,12E,15E,18E)-tetracosa-6,9,12,15,18-pentaenoate

C46H71O10P (814.4784596)

[(2S,3S,6S)-6-[(2S)-2-[(E)-hexadec-7-enoyl]oxy-3-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2S,3S,6S)-6-[(2S)-2-hexadecanoyloxy-3-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[hydroxy-[(5S)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] (11E,14E)-heptadeca-11,14-dienoate

C42H71O13P (814.4632045999999)

[(2S)-3-[hydroxy-[(5S)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-2-undecanoyloxypropyl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

C42H71O13P (814.4632045999999)

[(2S)-3-[hydroxy-[(5S)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-2-[(E)-pentadec-9-enoyl]oxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C42H71O13P (814.4632045999999)

[(2R)-1-[hydroxy-[(5S)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

C42H71O13P (814.4632045999999)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxypropyl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

C46H71O10P (814.4784596)

[3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropyl] (6E,9E,12E,15E,18E,21E)-tetracosa-6,9,12,15,18,21-hexaenoate

C46H71O10P (814.4784596)

[(2S,3S,6S)-6-[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-octadecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2S,3S,6S)-6-[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[(E)-octadec-11-enoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2R)-1-[hydroxy-[(5S)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

C42H71O13P (814.4632045999999)

[(2S,3S,6S)-6-[(2S)-2,3-bis[[(9E,12E)-heptadeca-9,12-dienoyl]oxy]propoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2S,3S,6S)-6-[(2S)-2-[(E)-hexadec-9-enoyl]oxy-3-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-[hydroxy-[(5S)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] (8E,11E,14E)-heptadeca-8,11,14-trienoate

C42H71O13P (814.4632045999999)

[(2S,3S,6S)-6-[(2S)-2-[(7E,10E,13E,16E)-docosa-7,10,13,16-tetraenoyl]oxy-3-dodecanoyloxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2S)-3-[hydroxy-[(5S)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-2-tridecanoyloxypropyl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

C42H71O13P (814.4632045999999)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropyl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

C46H71O10P (814.4784596)

[(2S)-3-[hydroxy-[(5S)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-2-[(E)-pentadec-9-enoyl]oxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C42H71O13P (814.4632045999999)

[(2S,3S,6S)-3,4,5-trihydroxy-6-[(2S)-2-[(5E,8E,11E)-icosa-5,8,11-trienoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropoxy]oxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2R)-1-[hydroxy-[(5S)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-3-[(E)-pentadec-9-enoyl]oxypropan-2-yl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C42H71O13P (814.4632045999999)

[(2S,3S,6S)-3,4,5-trihydroxy-6-[(2S)-3-[(8E,11E,14E)-icosa-8,11,14-trienoyl]oxy-2-[(E)-tetradec-9-enoyl]oxypropoxy]oxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2S,3S,6S)-6-[(2S)-3-[(E)-hexadec-9-enoyl]oxy-2-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

[(2S,3S,6S)-6-[(2S)-2-[(E)-hexadec-9-enoyl]oxy-3-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C43H74O12S (814.4900724)

SQDG(34:4)

C43H74O12S (814.4900724)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

DGDG O-27:5;O

C42H70O15 (814.471447)

DGDG O-28:4

C43H74O14 (814.5078304)

SMGDG O-33:6;O

C42H70O13S (814.453689)

SMGDG O-34:5

C43H74O12S (814.4900724)

SQDG 33:5;O

C42H70O13S (814.453689)

SQDG 34:4

C43H74O12S (814.4900724)

DGMG 28:4

C43H74O14 (814.5078304)

DGGA 37:8;O

C46H70O12 (814.486702)

PA 20:2/20:3;O4

C43H75O12P (814.499588)

PA 22:2/22:7;O

C47H75O9P (814.514843)

PA 22:4/22:5;O

C47H75O9P (814.514843)

PA 22:5/22:4;O

C47H75O9P (814.514843)

PA 22:6/20:5;O3

C45H67O11P (814.4420762)

PA 40:5;O4

C43H75O12P (814.499588)

PA 42:11;O3

C45H67O11P (814.4420762)

PA 44:9;O

C47H75O9P (814.514843)

BMP 40:10

C46H71O10P (814.4784596)

HBMP 37:4;O

C43H75O12P (814.499588)

PG 16:1/20:5;O3

C42H71O13P (814.4632045999999)

PG 36:6;O3

C42H71O13P (814.4632045999999)

PG 18:4_22:6

C46H71O10P (814.4784596)

PG 20:5/20:5

C46H71O10P (814.4784596)

PI O-14:0/20:5

C43H75O12P (814.499588)

PI O-14:1/20:4

C43H75O12P (814.499588)

PI O-16:1/18:4

C43H75O12P (814.499588)

PI O-16:2/18:3

C43H75O12P (814.499588)

PI P-14:0/20:4

C43H75O12P (814.499588)

PI P-14:0/20:4 or PI O-14:1/20:4

C43H75O12P (814.499588)

PI P-16:0/18:4

C43H75O12P (814.499588)

PI P-16:0/18:4 or PI O-16:1/18:4

C43H75O12P (814.499588)

PI P-16:1/18:3

C43H75O12P (814.499588)

PI P-16:1/18:3 or PI O-16:2/18:3

C43H75O12P (814.499588)

PI P-34:4

C43H75O12P (814.499588)

PI P-34:4 or PI O-34:5

C43H75O12P (814.499588)

PI 20:3/12:3;O

C41H67O14P (814.4268212)

PI 32:6;O

C41H67O14P (814.4268212)

PI 11:0_22:5

C42H71O13P (814.4632045999999)

PI 13:0_20:5

C42H71O13P (814.4632045999999)

PI 15:1_18:4

C42H71O13P (814.4632045999999)

PEth 42:9;O

C47H75O9P (814.514843)

PM 43:9;O

C47H75O9P (814.514843)

MGDG(40:14)

C49H66O10 (814.4655736000001)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

3-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-7-{3-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-9-methoxy-3,5-dimethyl-11h-pyrano[3,2-a]carbazol-10-yl}-3,5-dimethyl-11h-pyrano[3,2-a]carbazol-8-ol

C55H62N2O4 (814.4709332)

(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl (1r,2r,4as,6as,6br,8ar,10r,11r,12ar,12br,14bs)-1,10,11-trihydroxy-9,9-bis(hydroxymethyl)-1,2,6a,6b,12a-pentamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C41H66O16 (814.4350636)

(6s)-6-[(1s,3ar,3br,5s,5ar,7s,9ar,9br,11r,11ar)-7,11-dihydroxy-3a,3b,6,6,9a-pentamethyl-5-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-dodecahydro-1h-cyclopenta[a]phenanthren-1-yl]-2-methyl-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}hept-1-en-3-one

C42H70O15 (814.471447)

(3s)-n-(2-{[(3as,7r,7as)-4,7-dihydroxy-3h,3ah,6h,7h,7ah-imidazo[4,5-c]pyridin-2-yl]amino}-4,5-dihydroxy-6-[(c-hydroxycarbonimidoyloxy)methyl]oxan-3-yl)-6-{[(3s)-3-amino-6-{[(4s)-4,7-diamino-2-oxoheptyl]amino}-1-hydroxyhexylidene]amino}-3-[(1-hydroxyethylidene)amino]hexanimidic acid

C34H62N12O11 (814.4660782)

beesioside h

C42H70O15 (814.471447)

{"Ingredient_id": "HBIN017682","Ingredient_name": "beesioside h","Alias": "NA","Ingredient_formula": "C42H70O15","Ingredient_Smile": "CC1(C2CCC3C4(CC(C(C4(CCC35C2(C5)CCC1OC6C(C(C(C(O6)COC7C(C(C(C(O7)CO)O)O)O)O)O)O)CO)C8(CCC(O8)C(C)(C)O)C)O)C)C","Ingredient_weight": "815 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "2199","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "102024208","DrugBank_id": "NA"}

(4r,5s,6s)-6-[(1r,3as,3br,7s,9as,9br,11ar)-3a,6,6,9b,11a-pentamethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,10h,11h-cyclopenta[a]phenanthren-1-yl]-2,4,5-trihydroxy-2-methylheptan-3-one

C42H70O15 (814.471447)

6-(10,14-dihydroxy-7,7,12,16-tetramethyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl)-2-methyl-2-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-3-one

C42H70O15 (814.471447)

2-[(4-{[3,4-dihydroxy-5-(1-hydroxy-2-methoxyethyl)oxolan-2-yl]oxy}-3-hydroxy-5-(1-hydroxy-2-methoxyethyl)oxolan-2-yl)oxy]-9a,11a-dimethyl-1-(6-methyl-5-methylideneheptan-2-yl)-1h,2h,3h,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-4,5,6,7-tetrol

C42H70O15 (814.471447)

(3r,4s,5s)-6-{[(2r,3r,4ar,5r,6ar,6br,8s,10s,12ar,12br,14ar)-3,8,10-trihydroxy-4,4,6a,6b,9,9,12a-heptamethyl-2-{[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-hexadecahydro-1h-picen-5-yl]oxy}-4,5-dihydroxyoxan-3-yl acetate

C42H70O15 (814.471447)

(1r,2r,4r,5s,5ar,6r,7s,9ar,9br,11ar)-2-{[(2r,3r,4r,5s)-4-{[(2s,3r,4r,5s)-3,4-dihydroxy-5-[(1r)-1-hydroxy-2-methoxyethyl]oxolan-2-yl]oxy}-3-hydroxy-5-[(1r)-1-hydroxy-2-methoxyethyl]oxolan-2-yl]oxy}-9a,11a-dimethyl-1-[(2r)-6-methyl-5-methylideneheptan-2-yl]-1h,2h,3h,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-4,5,6,7-tetrol

C42H70O15 (814.471447)

(2s,3r,4s,5s,6r)-2-({2-[(5s)-5-[(1s,3r,8r,11s,12s,14s,15r,16r)-9,14-dihydroxy-7,7,12,16-tetramethyl-6-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]-5-methyloxolan-2-yl]propan-2-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol

C42H70O15 (814.471447)

(2r,5r,6s)-2-[(1r,2r,3ar,5as,7s,9as,11as)-2-hydroxy-9a,11a-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3ah,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-5-hydroxy-5-isopropyl-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptanoic acid

C41H66O16 (814.4350636)

(2s,3r,4r,5r,6s)-2-{[(2r,3r,4s,5s,6r)-2-{[(1s,3ar,3br,4s,5ar,7s,9as,9br,11ar)-1-[(2s,3s,4e)-2,3-dihydroxy-6-methoxy-6-methylhept-4-en-2-yl]-4-hydroxy-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

C43H74O14 (814.5078304)

(1r,3ar,5ar,6r,7s,9as,11ar)-1-[(2s,3r,4s,5r)-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-6,9a,11a-trimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-1h,2h,3h,3ah,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthrene-6-carboxylic acid

C42H70O15 (814.471447)

(2s,3r,4s,5s,6r)-2-({2-[(2s,5r)-5-[(1s,3r,6s,8s,9s,11r,12s,14s,15r,16r)-9,14-dihydroxy-7,7,12,16-tetramethyl-6-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]-5-methyloxolan-2-yl]propan-2-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol

C42H70O15 (814.471447)

2-{[14-hydroxy-16-(hydroxymethyl)-15-[5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12-trimethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-6-yl]oxy}-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol

C42H70O15 (814.471447)

6-(7,11-dihydroxy-3a,3b,6,6,9a-pentamethyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-dodecahydro-1h-cyclopenta[a]phenanthren-1-yl)-2-methyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}hept-1-en-3-one

C42H70O15 (814.471447)

(6r)-6-[(1s,3r,6s,8r,10s,11s,12s,14s,15r,16r)-6-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-10,14-dihydroxy-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]-2-hydroxy-2-methylheptan-3-one

C42H70O15 (814.471447)

2-{[5,10-dihydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-8-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C42H70O15 (814.471447)

(2r,3r,4r,5s)-2-{[(1r,2r,4r,5s,5as,7r,9ar,9br,11ar)-4-{[(2r,3r,4r,5s)-3,4-dihydroxy-5-[(1s)-1-hydroxy-2-methoxyethyl]oxolan-2-yl]oxy}-1-[(2r)-5-ethyl-6-methylheptan-2-yl]-5,7-dihydroxy-9a,11a-dimethyl-1h,2h,3h,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-2-yl]oxy}-5-[(1s)-1-hydroxy-2-methoxyethyl]oxolane-3,4-diol

C43H74O14 (814.5078304)

(2s,3r,4s,5s,6r)-2-{[(2r,3r,4s,5s,6r)-2-{[(1s,3r,6s,8r,9s,11s,12s,14s,15r,16r)-9,14-dihydroxy-15-[(2s,5r)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-6-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C42H70O15 (814.471447)

(2s,3r,4s,5s,6r)-2-{[(2r,3r,4s,5s,6r)-2-{[(1s,3r,6s,8r,9s,11s,12s,14s,15r,16r)-9,14-dihydroxy-15-[(2r,5s)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-6-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C42H70O15 (814.471447)

2-[(2-{[1-(2,3-dihydroxy-6-methoxy-6-methylhept-4-en-2-yl)-4-hydroxy-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl)oxy]-6-methyloxane-3,4,5-triol

C43H74O14 (814.5078304)

2-({3-hydroxy-10-[(10-hydroxy-2,6,10-trimethyl-8-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}dodeca-1,6,11-trien-3-yl)oxy]-3,7,11-trimethyldodeca-1,6,11-trien-5-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol

C42H70O15 (814.471447)

(2r,3r,4s,5s,6r)-2-{[(1s,3r,6s,8r,11s,12s,14s,15r,16s)-14-hydroxy-16-(hydroxymethyl)-15-[(2r,5s)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12-trimethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-6-yl]oxy}-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol

C42H70O15 (814.471447)

(6s)-6-[(1s,3ar,3br,5ar,7r,8r,9ar,9br,11r,11ar)-7,8,11-trihydroxy-3a,3b,6,6,9a-pentamethyl-dodecahydro-1h-cyclopenta[a]phenanthren-1-yl]-2-methyl-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}hept-1-en-3-one

C42H70O15 (814.471447)

7-{[5-({5-[(3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-4-methoxy-6-methyloxan-2-yl}oxy)-4-methoxy-6-methyloxan-2-yl]oxy}-1-(1-hydroxyethyl)-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-3a,10,11-triol

C42H70O15 (814.471447)

(2r,3r,4s,5s,6r)-2-{[(3s,4r,4ar,5r,6ar,6bs,8s,8as,10s,12as,14ar,14br)-5,10-dihydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-8-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C42H70O15 (814.471447)

6-(3a,6,6,9b,11a-pentamethyl-7-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,10h,11h-cyclopenta[a]phenanthren-1-yl)-2,4,5-trihydroxy-2-methylheptan-3-one

C42H70O15 (814.471447)

(2r,3r,4s,5s,6r)-2-{[(3r,5s,6e,10s)-3-hydroxy-10-{[(3s,6e,8s,10r)-10-hydroxy-2,6,10-trimethyl-8-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}dodeca-1,6,11-trien-3-yl]oxy}-3,7,11-trimethyldodeca-1,6,11-trien-5-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C42H70O15 (814.471447)

2-[(2r,3r,4s,5r,6s)-6-[(1s)-1-[(2s,5r,7s,8r,9s)-2-[(2s,2'r,3's,4'r,5'r)-5'-[(3s,4s,5r,6s)-6-hydroxy-4-methoxy-3,5,6-trimethyloxan-2-yl]-4'-methoxy-2,3'-dimethyl-[2,2'-bioxolan]-5-yl]-9-methoxy-2,8-dimethyl-1,6-dioxaspiro[4.5]decan-7-yl]ethyl]-4-methoxy-3,5-dimethyloxan-2-yl]ethaneperoxoic acid

C43H74O14 (814.5078304)

(1r,3as,3bs,7s,9ar,9bs,10r,11ar)-10-hydroxy-1-[(2r,5r)-6-hydroxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-2-yl]-3a,6,6,9b,11a-pentamethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,7h,8h,9h,9ah,10h,11h-cyclopenta[a]phenanthren-4-one

C42H70O15 (814.471447)

5-hydroxy-2-(2-hydroxy-9a,11a-dimethyl-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3ah,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-1-yl)-5-isopropyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptanoic acid

C41H66O16 (814.4350636)

(2r,3r,4s,5r,6r)-2-{[(1s,3r,6s,8r,11s,12s,14s,15r,16s)-14-hydroxy-16-(hydroxymethyl)-15-[(2s,5r)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12-trimethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-6-yl]oxy}-6-({[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol

C42H70O15 (814.471447)

4,5-dihydroxy-6-(hydroxymethyl)-3-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl 1,10,11-trihydroxy-9,9-bis(hydroxymethyl)-1,2,6a,6b,12a-pentamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C41H66O16 (814.4350636)

3-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-8-{3-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-9-methoxy-3,5-dimethyl-11h-pyrano[3,2-a]carbazol-10-yl}-3,5-dimethyl-11h-pyrano[3,2-a]carbazol-7-ol

C55H62N2O4 (814.4709332)

2-{[2-({9,14-dihydroxy-15-[5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-6-yl}oxy)-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C42H70O15 (814.471447)

6-(6-{[4,5-dihydroxy-6-(hydroxymethyl)-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-10,14-dihydroxy-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl)-2-hydroxy-2-methylheptan-3-one

C42H70O15 (814.471447)

2-({14-hydroxy-15-[1-(4-hydroxy-5,5-dimethyloxolan-2-yl)ethyl]-7,12,16-trimethyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-7-yl}methoxy)-6-(hydroxymethyl)oxane-3,4,5-triol

C42H70O15 (814.471447)

(2r,3r,4s,5s,6r)-2-{[(1s,3r,6s,7r,8r,11s,12s,14s,15r,16r)-14-hydroxy-15-[(1s)-1-[(2s,4s)-4-hydroxy-5,5-dimethyloxolan-2-yl]ethyl]-7,12,16-trimethyl-6-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-7-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C42H70O15 (814.471447)

(6r)-6-[(1s,3r,6s,8r,10s,11s,12s,14s,15r,16r)-10,14-dihydroxy-7,7,12,16-tetramethyl-6-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]-2-methyl-2-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptan-3-one

C42H70O15 (814.471447)

4-{[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3,5-dihydroxy-6-{[8,9,10-trihydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}oxane-2-carboxylic acid

C41H66O16 (814.4350636)

2-({2-[5-(9,14-dihydroxy-7,7,12,16-tetramethyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl)-5-methyloxolan-2-yl]propan-2-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol

C42H70O15 (814.471447)

[(2r,3r,4s,5s,6s)-2-hydroxy-6-[(1s)-1-[(2s,5r,7s,8r,9s)-2-[(2s,2'r,3's,4'r,5r,5'r)-5'-[(2s,3s,4s,5r,6s)-6-hydroxy-4-methoxy-3,5,6-trimethyloxan-2-yl]-4'-methoxy-2,3'-dimethyl-[2,2'-bioxolan]-5-yl]-9-methoxy-2,8-dimethyl-1,6-dioxaspiro[4.5]decan-7-yl]ethyl]-4-methoxy-3,5-dimethyloxan-2-yl]acetic acid

C43H74O14 (814.5078304)

2-({14-hydroxy-15-[5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-9-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol

C42H70O15 (814.471447)

(1r,3ar,3bs,7r,9ar,9bs,10s,11s,11as)-7-{[(2r,4s,5r,6r)-5-{[(2s,4s,5r,6r)-5-{[(2s,3r,4r,5r,6r)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-1-[(1r)-1-hydroxyethyl]-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-3a,10,11-triol

C42H70O15 (814.471447)

(2s,3s,4s,5r,6r)-6-{[(3s,4s,4ar,6ar,6bs,8r,8ar,9r,10r,12as,14ar,14br)-8,9,10-trihydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-4-{[(2s,3r,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3,5-dihydroxyoxane-2-carboxylic acid

C41H66O16 (814.4350636)

(1r,2r,4r,5s,5as,7r,9ar,9br,11ar)-2-{[(2r,3r,4r,5s)-4-{[(2s,3r,4r,5s)-3,4-dihydroxy-5-[(1s)-1-hydroxy-2-methoxyethyl]oxolan-2-yl]oxy}-3-hydroxy-5-[(1s)-1-hydroxy-2-methoxyethyl]oxolan-2-yl]oxy}-1-[(2r)-5-ethyl-6-methylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-4,5,7-triol

C43H74O14 (814.5078304)

(2r,3r,4s,5s,6r)-2-{[(1s,3r,6s,8s,9s,11r,12s,14s,15s,16r)-14-hydroxy-15-[(2r,5s)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-9-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C42H70O15 (814.471447)